Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Scle
- PDF / 1,168,839 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 109 Downloads / 177 Views
ORIGINAL RESEARCH
Work Productivity Outcomes Associated with Ocrelizumab Compared with Other DiseaseModifying Therapies for Multiple Sclerosis Edward E. Neuberger
. Ibrahim M. Abbass . Eddie Jones .
Natalie J. Engmann
Received: September 23, 2020 / Accepted: November 4, 2020 Ó The Author(s) 2020
ABSTRACT Objective: This study evaluated work and activity impairment in patients with multiple sclerosis (MS) treated with ocrelizumab (OCR) versus other disease-modifying therapies (DMTs). Methods: Data were obtained from the Adelphi Real World Disease Specific Programme for Multiple Sclerosis. Patients with relapsing–remitting or secondary progressive MS who completed surveys in 2018 and 2019 and received C 6 months of an eligible therapy, including OCR, injectable therapy, and oral therapy, were included. Outcomes were assessed using the patient-reported Work Productivity and Activity Impairment questionnaire. Doubly robust estimation, which combined propensity score weighting and regression modeling, was used to compare treatments, controlling for baseline clinical and demographic characteristics.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40120020-00224-1) contains supplementary material, which is available to authorized users. E. E. Neuberger (&) I. M. Abbass N. J. Engmann Genentech, Inc., South San Francisco, CA, USA e-mail: [email protected] E. Jones Adelphi Real World, Macclesfield, UK
Results: This study included 630 patients (OCR, n = 90; injectable DMT, n = 224; oral DMT, n = 316) with a mean (standard deviation) age of 42 (11) years. A greater proportion of OCR-treated patients had an Expanded Disability Status Scale score of C 3 at treatment initiation compared with those receiving oral and injectable DMTs (51 vs. 15% and 15%, respectively), and a smaller proportion of OCRtreated patients received treatment for C 1 year (43 vs. 90% and 92%, respectively). OCR-treated patients had higher odds of employment [odds ratio (95% confidence interval) 3.4 (1.5–7.7) vs. oral DMT, 5.6 (2.6–12.0) vs. injectable DMT], lower overall work productivity loss [difference (95% confidence interval) - 10.0% (- 6.1 to - 15.0%) vs. oral DMT, - 13.0% (- 8.5 to - 17.0%) vs. injectable DMT] and lower activity impairment [difference (95% confidence interval) - 11% (- 7.1 to - 16.0%) vs. oral DMT, - 9.7% (- 5.0 to - 14.0%) vs. injectable DMT]. Conclusion: This real-world evidence suggests that patients with MS treated with OCR experience lower work and activity impairment than patients treated with other DMTs.
PLAIN LANGUAGE SUMMARY Multiple sclerosis (MS) is the most common progressive neurological disease in young adults. It typically starts between the ages of 20
Neurol Ther
and 40 years—arguably some of the most productive years of an individual’s life—and it has a large impact on many aspects of everyday life for the rest of a person’s life. The reduction in the ability to do routine activities, including working, results in a large economic burden. Disease-
Data Loading...
